このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

早期慢性リンパ球性白血病または小リンパ球性リンパ腫患者の治療におけるオビヌツズマブ併用または非併用のアカラブルチニブ

2026年10月22日 更新者:Mayo Clinic

疾患進行のリスクが高い早期慢性リンパ性白血病/小リンパ球性リンパ腫 (CLL/SLL) 患者の治療において、アカラブルチニブをアカラブルチニブおよびオビヌツズマブと比較する無作為化第 2 相試験

This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.

調査の概要

詳細な説明

PRIMARY OBJECTIVES:

I. To compare the bone marrow minimal residual disease (MRD)-negative complete response (CR) rate of acalabrutinib alone and acalabrutinib/obinutuzumab in early stage asymptomatic chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients who are high and very high risk by CLL-International Prognostic Index (IPI). (Arms A and B) II. To evaluate time to first therapy (TFT) in early stage asymptomatic CLL/SLL patients with low and intermediate-risk by CLL-IPI. (Arm C)

SECONDARY OBJECTIVES:

I. To compare the safety of acalabrutinib alone and acalabrutinib/obinutuzumab in early stage asymptomatic CLL/SLL patients who are high and very high risk by CLL-IPI.

II. To compare the overall response rate (ORR), progression-free survival (PFS), time to next therapy (TNT) and overall survival (OS) of acalabrutinib alone and acalabrutinib/obinutuzumab in early stage asymptomatic CLL/SLL patients who are at high and very high risk by CLL-IPI.

III. To determine the progression-free survival (PFS) and overall survival (OS) in early stage asymptomatic CLL/SLL patients with low and intermediate risk by CLL-IPI.

EXPLORATORY OBJECTIVE:

I. To evaluate the quality of life using Functional Assessment of Cancer Therapy-General (FACT-G) quality of life (QOL) survey.

CORRELATIVE RESEARCH:

I. To compare the peripheral blood immune profile using 8-color flow cytometry, to assess changes in T-cells, natural killer (NK)-cells, and NK-T cells at baseline and during active treatment among patients receiving either acalabrutinib alone or acalabrutinib and obinutuzumab.

II. To determine changes in the peripheral blood immune profile using 8-color flow cytometry to assess changes in T-cells, NK-cells, and NK-T cells at baseline and during event monitoring in patients with low and intermediate risk by CLL-IPI.

III. Signal pathway studies-BTK, ERK, PLC gamma and S6 protein levels and phosphorylation status will be assessed by Western blot methodology using specific antibodies to pull down specific proteins from cell lysates.

IV. To confirm if in vitro cell killing is via apoptosis we will also assess PARP and caspase 3 cleavage.

V. Apoptotic protein studies-MCL-1, XIAP levels will be determined by Western blot methodology using specific antibodies to pull down these specific proteins from cell lysates.

VI. Bone marrow aspirates will be studied for hematopoietic function in two ways:

VIa. Estimation of colony forming capacity by purified hematopoietic stem cells (HSCs).

VIb. Evaluation of the levels of HSCs and their differentiated progeny (i.e. MPP, CMP, CLP).

VII. Paired bone marrow and blood samples will be evaluated for the levels of innate effector cells.

VIII. Perform targeted sequencing of 59 genes mainly grouped in 8 biological pathways: NOTCH1, B-cell signaling, deoxyribonucleic acid (DNA) damage response, chromatin modifiers, ribonucleic acid (RNA) metabolism, NF-kappaB pathway, cell cycle and apoptosis.

IX. Screen 2 genes previously associated with resistance to BTK inhibitors (BTK and PLCG2).

OUTLINE: Patients with high or very high risk CLL-IPI are randomized to Arm A or Arm B. Patients with intermediate or low risk are assigned to Arm C.

ARM A: Patients receive acalabrutinib orally (PO) twice daily (BID) on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment with acalabrutinib If MRD negative CR/CR with incomplete marrow recovery (CRi) is not achieved after 12 cycles.

ARM B: Patients receive acalabrutinib orally (PO) twice daily (BID) on days 1-28 and obinutuzumab intravenously (IV) on days 1, 2, 8, and 15 of cycle 1 and days 1 of subsequent cycles. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 cycles.

ARM C: Patients will be observed every 6 months for up to 2 years.

After completion of study treatment, patients are followed up every 6 months for up to 10 years.

研究の種類

介入

入学 (推定)

120

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Arizona
      • Scottsdale、Arizona、アメリカ、85259
        • 募集
        • Mayo Clinic in Arizona
        • コンタクト:
        • 主任研究者:
          • Talal Hilal, M.D.
    • Florida
      • Jacksonville、Florida、アメリカ、32224-9980
        • 積極的、募集していない
        • Mayo Clinic in Florida
    • Minnesota
      • Rochester、Minnesota、アメリカ、55905
        • 募集
        • Mayo Clinic in Rochester
        • 主任研究者:
          • Sameer A. Parikh, M.D.
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age >= 18 years

  • Diagnosis of:

    • Biopsy-proven small lymphocytic lymphoma (SLL) , or

    • Diagnosis of chronic lymphocytic leukemia (CLL) with a clonal B-cell population in the peripheral blood with immunophenotyping consistent with CLL as follows:

      • The population of lymphocytes share both B-cell antigens (CD19, CD20 [typically dim expression], or CD23) as well as CD5 in the absence of other pan-T-cell markers (CD3, CD2, etc.)
      • Clonality as evidenced by kappa or lambda light chain expression (typically dim immunoglobulin expression) or other genetic method (e.g. IGHV analysis)
      • Before diagnosing CLL or SLL, mantle cell lymphoma must be excluded by demonstrating a negative fluorescence in situ hybridization (FISH) analysis for t(11;14)(IgH/CCND1)
  • Patients must be previously untreated

    • Note: Prior chemotherapy or monoclonal antibody based therapy for treatment of CLL or SLL will be considered prior therapy; nutraceutical treatments with no established benefit in CLL (such as epigallocatechin gallate or EGCG, found in green tea or other herbal treatments or supplemental vitamins) will not be considered "prior treatment"; prior corticosteroid therapy for an indication other than CLL/SLL will not be considered "prior treatment"
  • All patients will undergo testing for prognostic factors according to the CLL-IPI (testing obtained =< 730 days prior to registration)

    • Note: If the results for any of the prognostic factors included in the CLL-IPI are unknown including IGVH mutation status results not being available due to a failed laboratory assay, the patient is not eligible
    • Note: When determining CLL-IPI, use most recent test results, if more than one result is available
    • Note: Patients with CLL-IPI risk category of high risk or very high risk (total score of 4-10) will be randomized to Arms A or B
    • Note: Patients with CLL-IPI risk category of low risk or intermediate risk (total score of 0-3) will be registered to Arm C
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

  • Provide written informed consent

  • Willing to provide blood and saliva samples for correlative research purposes

  • Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)

  • For high risk and very high risk CLL-IPI (Arms A and B) only: Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 30 days prior to randomization)

  • For high risk and very high risk CLL-IPI (Arms A and B) only: Platelet count >= 100,000/mm^3 (obtained =< 30 days prior to randomization)

  • For high risk and very high risk CLL-IPI (Arms A and B) only: Hemoglobin >= 11.0 g/dL (obtained =< 30 days prior to randomization)

  • For high risk and very high risk CLL-IPI (Arms A and B) only: Aspartate aminotransferase (aspartate transaminase [AST]) =< 3 x upper limit of normal (ULN) (obtained =< 30 days prior to randomization)

  • For high risk and very high risk CLL-IPI (Arms A and B) only: Creatinine =< 1.5 X ULN (obtained =< 30 days prior to randomization)

  • For high risk and very high risk CLL-IPI (Arms A and B) only: Total bilirubin =< 1.5 x upper limit of normal (ULN) (or total bilirubin =< 3.0 x ULN with direct bilirubin =< 1.5 x ULN in patients with well-documented Gilbert's syndrome (obtained =< 30 days prior to randomization)

  • For high risk and very high risk CLL-IPI (Arms A and B) only: Prothrombin time (PT), international normalized ratio (INR), and partial thromboplastin time (PTT) =< 1.5 X ULN OR if patient is receiving anticoagulant therapy and PT or PTT is within therapeutic range of intended use of coagulants (obtained =< 30 days prior to randomization)

  • Negative serum pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only

  • Will provide bone marrow aspirate sample for correlative research purposes

Exclusion Criteria:

  • Date of CLL/SLL diagnosis >= 24 months prior to registration

  • Prior exposure to ibrutinib or to a BCR inhibitor (e.g. Btk or PI3 kinase or Syk inhibitors) or a BCL-2 inhibitor (e.g. venetoclax)

  • Known central nervous system (CNS) lymphoma or leukemia

  • Patients with any of the following indications for chemotherapy:

    • Evidence of progressive marrow failure as manifested by the development of or worsening anemia (=< 11 g/dL) and/or thrombocytopenia (=< 100 x 10^9/L) not due to autoimmune disease

    • Symptomatic or progressive lymphadenopathy, splenomegaly or hepatomegaly

    • One or more of the following disease-related symptoms:

      • Weight loss >= 10% within the previous 6 months
      • Extreme fatigue attributed to CLL
      • Fevers >= 100.4 degrees Fahrenheit (F) for 2 weeks without evidence of infection
      • Drenching night sweats without evidence of infection
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

  • Patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  • Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm

  • Other active malignancy =< 2 years prior to registration; EXCEPTIONS: Non-melanotic skin cancer, carcinoma-in-situ of the cervix, or early stage prostate cancer

  • History of myocardial infarction =< 6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

  • For high risk and very high risk CLL-IPI (Arms A and B) only:

    • Any of the following:

      • Pregnant persons
      • Nursing persons
      • Persons of childbearing potential who are unwilling to employ highly effective contraception
    • Serologic status reflecting active hepatitis B or C infection

      • NOTE: Subjects with hepatitis B core antibody positive who are surface antigen negative or who are hepatitis C antibody positive will need to have a negative polymerase chain reaction (PCR) result before randomization; those who are hepatitis B surface antigen positive or hepatitis B PCR positive and those who are hepatitis C PCR positive will be excluded
    • History of stroke or intracranial hemorrhage within 6 months before randomization

    • History of bleeding diathesis (e.g. hemophilia, von Willebrand disease)

    • Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g. phenprocoumon) within 7 days of first dose of study drug and while on study

    • Requires treatment with a strong CYP3A inducer

    • Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening

    • History of confirmed progressive multifocal leukoencephalopathy (PML)

    • Received a vaccination with a live vaccine =< 28 days prior to randomization

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Arm A (acalabrutinib)

Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 cycles.

Correlative studies

Ancillary studies

他の名前:
  • 生活の質の評価

Given PO

他の名前:
  • ACP-196
  • Bruton チロシンキナーゼ阻害剤 ACP-196
実験的:Arm B (acalabrutinib, obinutuzumab)

Patients receive acalabrutinib PO BID on days 1-28 and obinutuzumab IV on days 1, 2, 8, and 15 of cycle 1 and days 1 of subsequent cycles. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 cycles.

Correlative studies

Ancillary studies

他の名前:
  • 生活の質の評価

Given IV

他の名前:
  • ガジバ
  • RO5072759
  • GA101
  • 抗CD20モノクローナル抗体 R7159
  • GA-101
  • huMAB(CD20)
  • R7159
  • RO 5072759
  • RO-5072759

Given PO

他の名前:
  • ACP-196
  • Bruton チロシンキナーゼ阻害剤 ACP-196
アクティブコンパレータ:Arm C (observation)

Patients will be observed every 6 months for up to 2 years.

Correlative studies

Ancillary studies

他の名前:
  • 生活の質の評価

Undergo observation

他の名前:
  • 観察
  • 能動的監視
  • 延期された治療
  • 期待される管理
  • 注意深く待っている

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Rate of minimal residual disease (MRD)-negative complete response (Arm A and Arm B)
時間枠:After 12 cycles (cycle 1-6 = 28 days, cycles 7 and beyond = 84 days)

Defined as an objective status of complete response (CR) or CR with incomplete marrow recovery (CRi) along with MRD negativity in the bone marrow by flow cytometry. Will be compared between the two arms. The proportion of successes will be estimated in each arm by the number of successes divided by the total number of evaluable patients. Ninety-five percent confidence intervals for the true success proportion will be calculated in each arm based on the normal approximation. Comparison of MRD-negative complete response rates between the two treatment groups will be performed using a one-sided z-test (based on normal approximation with pooled variance of standardized test statistics) at significance level 0.10.

After 12 cycles (cycle 1-6 = 28 days, cycles 7 and beyond = 84 days)
Time to first therapy (TFT) in patients (Arm C)
時間枠:After 12 cycles (one cycle = 6 months)

Defined as the time from the date of registration to the date of initiation of treatment for CLL.

After 12 cycles (one cycle = 6 months)

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall response rate (Arms A and B)
時間枠:Up to 10 years

Will be assessed in each arm by the number of patients who achieve complete remission (CR), complete remission with incomplete count recovery (CRi), clinical complete response (CCR), nodular partial response (nPR), or partial response (PR) at any time during treatment.

Up to 10 years
Progression-free survival (Arms A and B)
時間枠:From randomization up to 10 years

Defined as the time from randomization to the earliest date of documentation of disease progression or death due to any cause.

From randomization up to 10 years
Time to next therapy (Arms A and B)
時間枠:From the date of randomization up to 10 years

Defined as the time from the date of randomization to the date of initiation of subsequent treatment for CLL.

From the date of randomization up to 10 years
Overall survival (Arms A and B)
時間枠:From randomization up to 10 years

Defined as the time from randomization until death due to any cause.

From randomization up to 10 years
Progression-free survival (Arm C)
時間枠:From randomization up to 10 years

Defined as the time from randomization to the earliest date of documentation of disease progression or death due to any cause.

From randomization up to 10 years
Overall survival (Arm C)
時間枠:From randomization up to 10 years

Defined as the time from randomization until death due to any cause.

From randomization up to 10 years
Incidence of adverse events rates (Arms A and B)
時間枠:Up to 10 years

Will be assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed for each arm to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.

Up to 10 years

その他の成果指標

結果測定
メジャーの説明
時間枠
Quality of life
時間枠:Up to 10 years

Will be assessed using the Functional Assessment of Cancer Therapy-General (FACT-G), a 27-item questionnaire that measures Health-related quality of life (HRQoL) in cancer patients. Responses to each question are scored on a 5-point Likert scale ranging from 0 (Not at all) to 4 (Very much). Possible total scores range from 0-108, with higher scores indicating a better outcome/better quality QOL.

Up to 10 years
T-cells, natural killer (NK)-cells, and NK-T cells
時間枠:Baseline

Will be assessed in peripheral blood immune profile using 8-color flow cytometry. Values over time will be summarized graphically and descriptively. Paired sample approaches (Wilcoxon signed rank test) for these types of quantitative measures will be used to assess differences over time. Differences between treatments (Arms A and B only) will be assessed.

Baseline
Bone marrow hematopoiesis (Arms A and B)
時間枠:Up to 10 years

will be evaluated by estimation of colony forming capacity by purified hematopoietic stem cells (HSCs) and their differentiated progeny (i.e. multipotent progenitor, common myeloid progenitor, common lymphoid progenitor) as continuous measures. Degree of cytopenia in the peripheral blood will be evaluated on a continuous scale for each blood cell component (hemoglobin, platelets, etc.). In each arm, correlation between each blood cell component and its corresponding pre-cursor will be evaluated using Spearman's rank correlation coefficients.

Up to 10 years
Percent killing of chronic lymphocytic leukemia (CLL) B-cells (Arms A and B)
時間枠:After 12 courses

Will be measured as a continuous measure. In each arm, the relationship between percent killing and response (responder versus [vs.] non-responder) after 12 cycles of treatment will be evaluating using Wilcoxon's rank sum test.

After 12 courses
Somatic genetic mutations (Arms A and B)
時間枠:After 12 courses

Will be evaluated as present vs. absent for each gene. In each arm, the relationship between each mutation and response (responder vs. non-responder) after 12 cycles of treatment will be evaluated using Fisher's exact test.

After 12 courses

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Sameer A. Parikh, M.D.、Mayo Clinic in Rochester

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2018年9月10日

一次修了 (推定)

2028年11月11日

研究の完了 (推定)

2036年11月11日

試験登録日

最初に提出

2018年4月23日

QC基準を満たした最初の提出物

2018年5月3日

最初の投稿 (実際)

2018年5月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月26日

QC基準を満たした最後の更新が送信されました

2026年10月22日

最終確認日

2026年10月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する